Advertisement

Advertisement

CANF Stock Latest News

Can-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways

Company AnnouncementsCan-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways

Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu

PremiumThe Fly

Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu

11d ago

Can-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome

PremiumCompany Announcements

Can-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome

11d ago

Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation

PremiumCompany Announcements

Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation

25d ago

Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer

PremiumCompany Announcements

Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer

1M ago

Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson

PremiumThe FlyCan-Fite BioPharma secures Australian Patent Office allowance for namodenoson

1M ago

Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson

Company Announcements

Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson

1M ago

Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial

The Fly

Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial

1M ago

Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright

PremiumThe Fly

Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright

1M ago

Can-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial

PremiumCompany Announcements

Can-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial

1M ago

Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint

PremiumThe Fly

Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint

1M ago

Can-Fite BioPharma Wins Japanese Patent for Namodenoson’s Anti-Obesity Technology

PremiumCompany Announcements

Can-Fite BioPharma Wins Japanese Patent for Namodenoson’s Anti-Obesity Technology

2M ago

Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists

PremiumThe FlyCan-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists

2M ago

Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study

Company Announcements

Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study

2M ago

Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026

Company Announcements

Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026

2M ago

Can-Fite BioPharma Shareholders Approve All Proposals at 2026 Annual Meeting

PremiumCompany Announcements

Can-Fite BioPharma Shareholders Approve All Proposals at 2026 Annual Meeting

2M ago

Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer

PremiumCompany Announcements

Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer

2M ago

Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum

PremiumCompany Announcements

Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum

3M ago

Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis

PremiumCompany Announcements

Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis

3M ago

Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

PremiumThe FlyCan-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

3M ago

Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data

Company Announcements

Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data

3M ago

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

The Fly

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >